ATE516025T1 - Verwendung zur behandlung von fettsucht und diabetes - Google Patents
Verwendung zur behandlung von fettsucht und diabetesInfo
- Publication number
- ATE516025T1 ATE516025T1 AT07793743T AT07793743T ATE516025T1 AT E516025 T1 ATE516025 T1 AT E516025T1 AT 07793743 T AT07793743 T AT 07793743T AT 07793743 T AT07793743 T AT 07793743T AT E516025 T1 ATE516025 T1 AT E516025T1
- Authority
- AT
- Austria
- Prior art keywords
- diabetes
- obesity
- carnitine
- caffeine
- arginine
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
- 229960003121 arginine Drugs 0.000 abstract 2
- 229960001948 caffeine Drugs 0.000 abstract 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 abstract 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 abstract 2
- 235000008696 isoflavones Nutrition 0.000 abstract 2
- 235000020712 soy bean extract Nutrition 0.000 abstract 2
- 102000011690 Adiponectin Human genes 0.000 abstract 1
- 108010076365 Adiponectin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 101150110386 SLC2A4 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003579 anti-obesity Effects 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060106362A KR101069502B1 (ko) | 2006-10-31 | 2006-10-31 | 비만 및 당뇨병 개선용 경구용 조성물 |
| PCT/KR2007/004160 WO2008054059A1 (en) | 2006-10-31 | 2007-08-29 | Use for treating obesity and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516025T1 true ATE516025T1 (de) | 2011-07-15 |
Family
ID=39344385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07793743T ATE516025T1 (de) | 2006-10-31 | 2007-08-29 | Verwendung zur behandlung von fettsucht und diabetes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100056560A1 (de) |
| EP (1) | EP2086532B1 (de) |
| KR (1) | KR101069502B1 (de) |
| CN (1) | CN101534817A (de) |
| AT (1) | ATE516025T1 (de) |
| WO (1) | WO2008054059A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367122B2 (en) | 2008-06-11 | 2013-02-05 | Biochemics, Inc. | Control of blood vessel physiology to treat skin disorders |
| KR20100025299A (ko) * | 2008-08-27 | 2010-03-09 | 씨제이제일제당 (주) | 비만 또는 당뇨병의 예방 또는 개선용 조성물 |
| MX349176B (es) | 2008-09-22 | 2017-07-14 | Biochemics Inc | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. |
| US9278233B2 (en) | 2008-12-04 | 2016-03-08 | Biochemics, Inc. | Methods and compositions for tattoo removal |
| WO2010077074A2 (ko) * | 2008-12-29 | 2010-07-08 | 주식회사 에이.비.아이 | 아르기닌 치아졸리딘 카르복실산 또는 그 유도체를 포함하는 당뇨병 치료제 |
| KR101640258B1 (ko) * | 2010-07-05 | 2016-07-15 | 주식회사 엘지생활건강 | 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물 |
| US9409006B2 (en) | 2011-04-10 | 2016-08-09 | David Hirshberg | Fat removal device and obesity treatment |
| CN103607959B (zh) | 2011-04-21 | 2016-07-27 | 皇家飞利浦有限公司 | 用于三维超声中导管的可视化的mpr 切片选择 |
| KR101215277B1 (ko) * | 2011-12-16 | 2012-12-26 | 계명대학교 산학협력단 | γ-폴리글루탐산 및 아이소플라본을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 당뇨의 예방 또는 치료용 조성물 |
| CN103948581B (zh) * | 2014-02-26 | 2018-05-08 | 青岛大学医学院附属医院 | 左卡尼汀联合l-精氨酸在制备治疗糖尿病视网膜病变神经损伤药物中的应用 |
| US10307389B2 (en) * | 2014-04-08 | 2019-06-04 | Neurovive Pharmaceutical Ab | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation |
| EP3129016B1 (de) | 2014-04-08 | 2018-06-06 | Neurovive Pharmaceutical AB | Neuartige zelldurchlässige succinatverbindungen |
| CA2995158C (en) * | 2015-08-28 | 2021-05-11 | Caliway Biopharmaceuticals Co., Ltd. | A pharmaceutical composition for reducing local fat and uses thereof |
| ES2906316T3 (es) * | 2018-12-10 | 2022-04-18 | Aphaia Ip Ag | Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas |
| CN111357979A (zh) * | 2019-12-26 | 2020-07-03 | 浙江欧谱生物科技有限公司 | 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用 |
| KR20250042478A (ko) | 2023-09-20 | 2025-03-27 | 바이오모아메디칼 주식회사 | 혈당, 또는 체지방 또는 내장지방 감소용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0511587A1 (de) * | 1991-04-26 | 1992-11-04 | Takeda Chemical Industries, Ltd. | Schlankmachende Zusammensetzung |
| US6143786A (en) * | 1999-02-02 | 2000-11-07 | Novartis Nutrition Ag | Oral arginine and insulin secretion |
| KR100520408B1 (ko) * | 2003-03-25 | 2005-10-10 | 주식회사 태평양 | 비만개선용 조성물 |
| KR100998990B1 (ko) * | 2003-12-29 | 2010-12-09 | (주)아모레퍼시픽 | 슬리밍용 조성물 |
| US20060252706A1 (en) * | 2003-04-24 | 2006-11-09 | Ji-Hyun Kim | Composition for slimming |
| US7759318B1 (en) * | 2004-05-28 | 2010-07-20 | Isis Pharmaceuticals, Inc. | Identification of novel pathways, genes and promoter motifs regulating adipogenesis |
| KR100522253B1 (ko) * | 2005-03-09 | 2005-10-18 | 주식회사 태평양 | 비만개선용 식품 조성물 |
-
2006
- 2006-10-31 KR KR1020060106362A patent/KR101069502B1/ko active Active
-
2007
- 2007-08-29 US US12/447,800 patent/US20100056560A1/en not_active Abandoned
- 2007-08-29 CN CNA2007800408288A patent/CN101534817A/zh active Pending
- 2007-08-29 WO PCT/KR2007/004160 patent/WO2008054059A1/en not_active Ceased
- 2007-08-29 AT AT07793743T patent/ATE516025T1/de not_active IP Right Cessation
- 2007-08-29 EP EP07793743A patent/EP2086532B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101534817A (zh) | 2009-09-16 |
| US20100056560A1 (en) | 2010-03-04 |
| EP2086532A1 (de) | 2009-08-12 |
| WO2008054059A1 (en) | 2008-05-08 |
| EP2086532A4 (de) | 2009-11-11 |
| EP2086532B1 (de) | 2011-07-13 |
| KR101069502B1 (ko) | 2011-09-30 |
| KR20080038870A (ko) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2086532A4 (de) | Verwendung zur behandlung von fettsucht und diabetes | |
| EA201490913A1 (ru) | Лекарственные формы для лечения сахарного диабета | |
| EA201101111A1 (ru) | Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами | |
| TWI631141B (zh) | 用來抑制經活化受體之胜肽及其於化妝或醫藥組成物中之用途 | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| EA201490982A1 (ru) | Аналоги глюкагона | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| Kim et al. | Protective effects of standardized Siegesbeckia glabrescens extract and its active compound kirenol against UVB-induced photoaging through inhibition of MAPK/NF-κB pathways | |
| EA201171197A1 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| MY146662A (en) | Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
| BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| RU2011119988A (ru) | Композиции инсулинов длительного действия | |
| MX2015002666A (es) | Metodo y composicion para tratar hiperglicemia. | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| EA201290865A1 (ru) | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона | |
| UA111360C2 (uk) | ПОХІДНІ 4-АМІНО-7,8-ДИГІДРОПІРИМІДО[4,5-f][1,4]ОКСАЗЕПІН-5-ОНУ ЯК ІНГІБІТОРИ ДІАЦИЛГЛІЦЕРОЛАЦИЛТРАНСФЕРАЗИ | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| GB2476202A (en) | Novel choline cocrystal of epalrestat | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| WO2018169282A3 (ko) | Atpif1을 함유하는 당뇨 치료용 약학조성물 | |
| EA201391592A1 (ru) | Местная композиция для лечения гиперкератотической кожи | |
| MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
| NZ597905A (en) | L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin | |
| ATE396697T1 (de) | Zuckerlacton enthaltende zusammensetzung zur haarbehandlung | |
| ATE464895T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |